Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
UCB supports a range of activities to help raise awareness about several neurological and immunological conditions, such as Parkinson’s disease. ????️Follow #UniteForParkinsons and #UCB hashtags to see more on this.
— UCB News (@ucb_news) 21.09.2018 -
RT @The_MRC: Monoclonal antibodies are successful drugs used to treat millions of patients. But how to go about finding new ones? ???? Industr…
— UCB News (@ucb_news) 21.09.2018 -
Thinking about taking part in clinical studies? UCB is committed to ensure that participants make informed decisions about participating in the studies #UCB90 #InspiredByPatients #DrivenByScience https://t.co/KptME0XV7v https://t.co/oOLyKNQUNO
— UCB News (@ucb_news) 19.09.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
